Centocor tumor marker reclassification petition to be approved "shortly" via FDA letter.
This article was originally published in The Gray Sheet
SERUM TUMOR MARKER MOVE TO CLASS II WILL BE OUTLINED IN LETTER TO CENTOCOR which FDA plans to send "shortly," agency staffers say. Upon issuance of the letter, serum tumor markers will be considered Class II products and will go to market via 510(k), FDA says. A subsequent order in the Federal Register will formalize FDA's decision to downclassify serum tumor markets.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.